Skip to main content
placeholder image

A phase II study of tasisulam sodium (LY573636) as second-line treatment for patients with unresectable or metastatic melanoma.

Journal Article


Abstract


UOW Authors


  •   Clingan, Phillip (external author)

Publication Date


  • 2010

Citation


  • Kirkwood, J. M., Gonzalez, R., Reintgen, D. S., Clingan, P. R., McWilliams, R. R., Ilaria, R. L., . . . Millward, M. (2010). A phase II study of tasisulam sodium (LY573636) as second-line treatment for patients with unresectable or metastatic melanoma.. Journal of Clinical Oncology, 28(15_suppl), 8541. doi:10.1200/jco.2010.28.15_suppl.8541

Web Of Science Accession Number


Start Page


  • 8541

End Page


  • 8541

Volume


  • 28

Issue


  • 15_suppl

Abstract


UOW Authors


  •   Clingan, Phillip (external author)

Publication Date


  • 2010

Citation


  • Kirkwood, J. M., Gonzalez, R., Reintgen, D. S., Clingan, P. R., McWilliams, R. R., Ilaria, R. L., . . . Millward, M. (2010). A phase II study of tasisulam sodium (LY573636) as second-line treatment for patients with unresectable or metastatic melanoma.. Journal of Clinical Oncology, 28(15_suppl), 8541. doi:10.1200/jco.2010.28.15_suppl.8541

Web Of Science Accession Number


Start Page


  • 8541

End Page


  • 8541

Volume


  • 28

Issue


  • 15_suppl